Welcome to our dedicated page for Vera Therapeutics news (Ticker: VERA), a resource for investors and traders seeking the latest updates and insights on Vera Therapeutics stock.
Vera Therapeutics develops treatments for serious immunological diseases, with company updates centered on atacicept, a self-administered fusion protein designed to block BAFF and APRIL activity involved in autoantibody production. News commonly covers the atacicept program in IgA nephropathy, related autoimmune kidney disease research, clinical data from the ORIGIN and PIONEER programs, FDA regulatory communications, and preparations tied to potential commercialization.
Other recurring developments include quarterly financial results, balance sheet and financing commentary, participation in health care conferences, board and executive appointments, and equity-based inducement awards under Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics, Inc. (NASDAQ: VERA) announced that interim data from its Phase 2 trial of MAU868 versus placebo for treating BK Virus (BKV) in kidney transplant patients will be shared in a late-breaking presentation at the American Transplant Congress (ATC) 2022 on June 4, 2022. The trial aims to assess MAU868's safety and efficacy and represents a significant step in addressing BKV, a serious complication for transplant recipients. Vera holds exclusive worldwide rights for MAU868, acquired from Amplyx Pharmaceuticals, a Pfizer subsidiary.
Vera Therapeutics (Nasdaq: VERA) has appointed Michael M. Morrissey, Ph.D., as chairman of its board of directors. Dr. Morrissey, former president and CEO of Exelixis, brings extensive biopharmaceutical experience and expertise in drug development, regulatory processes, and commercialization. His leadership is expected to guide Vera as it transitions from late-stage clinical programs to commercialization efforts. The company focuses on innovative treatments for serious immunological diseases, including its lead candidate atacicept for IgA nephropathy and lupus nephritis.
Vera Therapeutics (Nasdaq: VERA) reports significant progress in its clinical pipeline, including the Phase 2b ORIGIN trial for atacicept, expecting topline data in Q4 2022. The company strengthened its financial position with an $80.2 million equity offering and plans a Phase 3 trial for atacicept in lupus nephritis. Furthermore, the acquisition of MAU868 aims to treat BK Virus infections, with interim results expected mid-2022. Vera ended 2021 with $79.7 million in cash, showing a reduced net loss of $16.8 million for Q4 2021, compared to $42.9 million the previous year.
Vera Therapeutics will host a KOL webinar on March 29, 2022, discussing its lead asset MAU868, a monoclonal antibody targeting BK Virus (BKV) infections in kidney transplant patients. Renowned nephrologist Dr. Stanley C. Jordan will present, emphasizing that BKV is a major cause of transplant-related complications. MAU868 is currently in a Phase 2 trial, showing promising results in lowering BK plasma viral load. There are no approved BKV treatments in the U.S., making this development critical for transplant care.
Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company, will host a business update call on March 24, 2022, at 8:00 a.m. ET. The company is focused on developing transformative treatments for serious immunological diseases. Investors can participate via a toll-free number or an international line, and a webcast will be available 15 minutes prior to the call. Vera's lead candidate, atacicept, targets autoimmune diseases such as IgA nephropathy and lupus nephritis. For details, visit www.veratx.com.
Vera Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Marshall Fordyce, MD, will present at the 42nd Annual Cowen Health Care Conference from March 7-9, 2022. The presentation is scheduled for March 9 from 2:10-3:10 PM ET in a corporate panel discussion format. A live audio webcast will be available for those interested. Vera Therapeutics focuses on developing treatments for serious immunological diseases, with its lead product candidate, atacicept, targeting autoimmune diseases like IgA nephropathy and lupus nephritis.
Vera Therapeutics has successfully closed a public offering of 5,742,026 shares of Class A common stock at $15.00 per share, raising approximately $86.1 million in gross proceeds. This includes the full exercise of the underwriters’ option for an additional 748,959 shares. The offering was managed by J.P. Morgan, Cowen, and Evercore ISI. Registration statements for the securities became effective on February 9 and 10, 2022, and all shares offered were sold by Vera.
Vera Therapeutics, Inc. (Nasdaq: VERA) announced a public offering of 4,993,067 shares of Class A common stock priced at $15.00 per share, aiming to raise approximately $74.9 million before expenses. All shares are offered by the company, with an additional option for underwriters to purchase 748,959 shares within 30 days. The offering is set to close on February 14, 2022, pending customary conditions. J.P. Morgan, Cowen, and Evercore ISI are acting as the joint book-running managers. The securities registration was approved by the SEC on February 9 and 10, 2022.
On February 7, 2022, Vera Therapeutics announced a public offering of 4,000,000 shares of its Class A common stock, with all shares being offered by the company. The underwriters may purchase an additional 600,000 shares within a 30-day option. The offering is subject to market conditions and customary closing prerequisites. J.P. Morgan, Cowen, and Evercore ISI are managing the offering. The registration statement is filed with the SEC and is accessible online. Vera Therapeutics focuses on treatments for serious immunological diseases with candidates like atacicept and MAU868.
Vera Therapeutics announced plans to initiate a Phase 3 trial for atacicept in treating lupus nephritis (LN) following positive feedback from the FDA. The trial will assess the efficacy and safety of atacicept in patients with LN, addressing a critical need as current treatments have limited effectiveness. The trial features a 52-week treatment period, focusing on complete renal response as the primary endpoint. Vera is also advancing trials for other indications, including immunoglobulin A nephropathy (IgAN) and BK virus infections in kidney transplant patients.